Plain-English translation of NCT06003556 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a specialized imaging scan called PSMA PET can help doctors better detect all areas of prostate cancer before performing focal therapy—a newer treatment that targets only the cancerous region of the prostate rather than the entire gland. The scan uses a radioactive tracer to light up cancer cells, giving doctors a clearer picture of where the disease is located. The goal is to make sure no cancer is missed before treatment begins.
Current imaging and biopsy techniques sometimes miss cancer on parts of the prostate that patients thought were healthy, leading to incomplete treatment and cancer recurrence. This trial aims to test whether the new imaging approach can catch these hidden cancers and help doctors choose the right treatment for each patient.
You likely qualify if…
You likely don't qualify if…
Half of the participants will receive a specialized imaging scan (PSMA PET) before their focal therapy treatment, while the other half will proceed directly to treatment without the extra scan. All participants will then be monitored with imaging and biopsy again 12 months after their treatment to see if the cancer has been controlled. The trial will help determine whether the extra scan upfront improves outcomes and prevents cancer from being missed.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Canada